Givaudan ends research collaboration with Redpoint

by Jeff Gelski
Share This:

EWING, N.J. — Givaudan, Vernier, Switzerland, has terminated its research and development collaboration and licensing agreement with Redpoint Bio Corp. The agreement signed in March of 2007 was designed to discover and develop sweetener and savory enhancers and bitter blocker compounds.

"While we are disappointed with the conclusion of our partnership with Givaudan, we believe that Redpoint’s technology platform continues to provide opportunities to discover new products for both the food and beverage and pharmaceutical industries," said Dr. Ray Salemme, Ph. D., chief executive officer of Ewing-based Redpoint Bio. "We continue to advance our taste modulation discovery programs, in addition to investigating potential therapeutic applications for our compounds for the treatment of diabetes and obesity.

"We recognize that due to strategic changes in focus, Givaudan was not able to continue with our collaboration. However, we continue to maintain a positive relationship with Givaudan, the world’s leading company in the flavors and fragrances industry."

Comment on this Article
We welcome your thoughtful comments. Please comply with our Community rules.



The views expressed in the comments section of Food Business News do not reflect those of Food Business News or its parent company, Sosland Publishing Co., Kansas City, Mo. Concern regarding a specific comment may be registered with the Editor by clicking the Report Abuse link.